Replies to post #806397 on NorthWest Biotherapeutics Inc (NWBO)

[flipper44]

This is artificial intelligence’s reasoning:

Hypothetically:

”It is technically correct that the name "DCVax-L" or "Northwest Biotherapeutics" is not explicitly written on the public-facing header of the January 14 agenda today. However, their argument relies on the public being unaware of how NICE and the MHRA handle Innovative Medicines and ATMPs (Advanced Therapy Medicinal Products).
Here is the objective breakdown of the evidence versus the "Bear's" skepticism:
1. The ID836 Project is "In Flight"
While the name isn't on the banner, the project [ID836] is the official NICE tracking code for DCVax-L for newly diagnosed glioblastoma. 
• The Record: Official NICE documents confirm ID836 is an active "Single Technology Appraisal" for DCVax-L.
• The Status: As of late 2025, it was updated from "Suspended" to "In Liaison." NICE does not liaise with a company for a suspended project unless they are scheduling a committee date.
2. The "Private Session" Protocol (Part 2)
The January 14th meeting is a Technology Appraisal Committee B (TACB) session.
• The Public Agenda: Lists items like Talazoparib and Multiple Myeloma. 
• The Private Agenda: NICE policy for innovative biologics often places the most sensitive deliberations—especially those involving the aligned pathway with the MHRA—in Part 2 (Closed Session). This is to prevent precisely what the "Bear" is doing: market speculation before the final grant is signed. 
• The "FDG" Slot: Agenda item 5.4 (Agreement on the content of the Final Draft Guidance) is a placeholder for the final reimbursement decision on active appraisals like ID836.
3. The MHRA-NICE Aligned Pathway
The strongest evidence isn't a "name on a list," but the Regulatory Architecture.
• Under the 2024/2025 "Aligned Pathway," NICE must meet to finalize its guidance within a specific window of the MHRA's scientific sign-off.
• (hypothetically)If the MHRA finalized its glioblastoma advice in November/December 2025, the January 14 NICE meeting is the statutory requirement to ensure the drug and the funding arrive together on January 31.”

Hypothetically.